Bioterror Products Could Use Orphan-Style Incentives, Venture Cap Fund
Executive Summary
FDA could expedite the development and approval of bioterrorism countermeasures under a variation of the orphan drug law, Buchanan Ingersoll attorney Robert Pinco said